Intra-vitreal administration of anti-vascular endothelial growth factor (anti-VEGF) is variably used as an addition to vitrectomy to improve the outcome of surgery by reducing the incidence of intra-operative and post-operative vitreous hemorrhage and to ease the delamination of fibrovascular membranes [11,12,13]. This evidence concerns the gene VEGFA and vitreous hemorrhage.